David Mourar

David Mourar serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical scientific and operational resources. He manages a diverse portfolio of contracts centered on laboratory diagnostics, biomedical research enablement, and data infrastructure services, ensuring timely delivery of capabilities essential for infectious disease surveillance and response. His work directly enables CDC’s scientific missions by securing advanced diagnostic systems, computational tools, and support services that underpin national public health operations. Mourar maintains consistent partnerships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid, reflecting a preference for established entities with proven expertise in high-compliance, mission-critical domains. His contracting patterns emphasize technical rigor and regulatory alignment, particularly in areas requiring FDA-regulated products, CLIA-compliant laboratory systems, and secure data analytics platforms. These relationships are built on long-term performance reliability and adherence to federal biosafety and data integrity standards. His set-aside preferences show a strong orientation toward open competition, with 84.2% of awards issued under full and open procedures. The remaining 15.8% are competed under the 8(a) program, indicating a measured but deliberate commitment to small business participation without compromising operational urgency or technical capability. This balance reflects CDC’s need for scalable, high-assurance solutions while still fostering innovation from disadvantaged business enterprises. Mourar’s procurement focus is heavily concentrated in NAICS 541512 (Computer Systems Design Services) and 325413 (In-Vitro Diagnostic Substance Manufacturing), underscoring his specialization in digital health infrastructure and laboratory diagnostics. He regularly procures next-generation molecular testing platforms, real-time epidemiological data systems, and integrated biosurveillance tools, demonstrating deep technical fluency in public health informatics and clinical diagnostics. His expertise ensures that CDC’s acquisition strategy remains aligned with evolving scientific and operational demands in global health security.